Sutimlimab in CAD Safety Analysis
Pooled Post Hoc Analysis of Safety Outcomes From Phase III CARDINAL and CADENZA Trials of Sutimlimab in Cold Agglutinin Disease

Released: December 14, 2023

Activity

Progress
1
Course Completed